Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis [Phase 3]

View source ↗

Summary

This update summarizes results from a Phase 3 study of obinutuzumab in ISN/RPS 2003 Class III or IV lupus nephritis. The trial status is active but not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Gazyva (Obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lupus Nephritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-06